Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 8 Multivariate analysis of time to progression using Cox proportional hazard model

Population	Prognostic factors	n1	c1	HR (95%CI)	P value
TARE_alone (n = 63)	Child-pugh class
	A	57	24	0.32 (0.09-1.10)	0.073
	B	6	3
	Lobar involvement
	Unilobar	33	16	0.51 (0.26-1.00)	0.051
	Bilobar	30	11
TARE_sorafenib (n = 81)	ECOG2
	0	40	8	0.85 (0.59-1.22)	0.370
	1	40	16
	MVI
	Absence	56	12	1.15 (0.74-1.80)	0.532
	Presence	24	11
	EHD
	Absence	60	23	0.37 (0.24-0.56)	< 0.001
	Presence	21	1
	IHT
	≤ 50%	37	15	0.72 (0.49-1.06)	0.096
	> 50%	44	9

¹Total patients (n) and censored patients (c).

²ECOG 2 (n = 1) and ECOG 3 (n = 0) excluded.

TARE: Transarterial radioembolization; ECOG: Eastern cooperative oncology group; MVI: Macrovascular invasion; EHD: Extrahepatic disease; IHT: Intrahepatic tumor.